Reversing the effects of ceramide imbalance via anti-ceramide immunotherapy is an effective therapy for diabetic retinopathy

This is the authors' abstract. We don't add key points for this paper.

Dorweiler TF, Singh A, Ganju A, Lydic TA, Glazer LC, Kolesnick RN, et al. Diabetic retinopathy is a ceramidopathy reversible by anti-ceramide immunotherapy. Cell Metab. 2024;36:1521–33.e5. Google Scholar Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910–8. Google Scholar Wilkerson JL, Tatum SM, Holland WL, Summers SA. Ceramides are fuel gauges on the drive to cardiometabolic disease. Physiol Rev. 2024;104:1061–119. Google Scholar Raichur S, Wang ST, Chan PW, Li Y, Ching J, Chaurasia B, et al. CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 2014;20:687–95. Google Scholar Busik JV. Lipid metabolism dysregulation in diabetic retinopathy. J Lipid Res. 2021;62:100017. Google Scholar Download references